In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
The price of Monte Rosa Therapeutics Inc (NASDAQ: GLUE) closed at $5.75 in the last session, up 4.17% from day before closing price of $5.52. In other words, the price has increased by $4.17 from its previous closing price. On the day, 0.91 million shares were traded. GLUE stock price reached its highest trading level at $5.81 during the session, while it also had its lowest trading level at $5.35.
Ratios:
We take a closer look at GLUE’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 6.03 and its Current Ratio is at 6.03. In the meantime, Its Debt-to-Equity ratio is 0.21 whereas as Long-Term Debt/Eq ratio is at 0.19.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Wells Fargo on December 19, 2024, Downgraded its rating to Equal Weight and sets its target price to $11 from $14 previously.
On February 15, 2024, Wedbush started tracking the stock assigning a Outperform rating and target price of $11.
Wells Fargo Upgraded its Equal Weight to Overweight on January 03, 2023, while the target price for the stock was maintained at $18.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Oct 28 ’24 when Versant Venture Capital VI, L. sold 89,990 shares for $9.66 per share. The transaction valued at 869,240 led to the insider holds 2,007,948 shares of the business.
Versant Venture Capital VI, L. sold 67,905 shares of GLUE for $621,801 on Oct 29 ’24. The 10% Owner now owns 1,573,453 shares after completing the transaction at $9.16 per share. On Oct 28 ’24, another insider, Wallace Owen B., who serves as the Officer of the company, bought 20,000 shares for $12.00 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GLUE now has a Market Capitalization of 353261024 and an Enterprise Value of 140639360. For the stock, the TTM Price-to-Sale (P/S) ratio is 23.60 while its Price-to-Book (P/B) ratio in mrq is 1.72. Its current Enterprise Value per Revenue stands at 9.392 whereas that against EBITDA is -1.162.
Stock Price History:
The Beta on a monthly basis for GLUE is 1.40, which has changed by 0.03759396 over the last 52 weeks, in comparison to a change of 0.23883796 over the same period for the S&P500. Over the past 52 weeks, GLUE has reached a high of $12.40, while it has fallen to a 52-week low of $3.21. The 50-Day Moving Average of the stock is -23.76%, while the 200-Day Moving Average is calculated to be -1.74%.
Shares Statistics:
According to the various share statistics, GLUE traded on average about 2.94M shares per day over the past 3-months and 915950 shares per day over the past 10 days. A total of 61.38M shares are outstanding, with a floating share count of 45.95M. Insiders hold about 25.21% of the company’s shares, while institutions hold 68.65% stake in the company. Shares short for GLUE as of 1735603200 were 9144923 with a Short Ratio of 3.11, compared to 1732838400 on 11054976. Therefore, it implies a Short% of Shares Outstanding of 9144923 and a Short% of Float of 27.189999999999998.
